Bendamustine and Radiation Therapy in Treating Patients With Brain Metastases Caused by Solid Tumors

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 8% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-01-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: brainchemotherapymyelomametastasescell
  Phrases that lowered it: trial islymphomasolidscoreweeks
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Responsible party: sponsor investigator (raises risk) · Design
• Drug's FAERS reports with a death: 20% (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 100% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design
• Disease area, neurology: Yes (raises risk) · Disease area
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Allocation: not applicable (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study Bendamustine Concurrent Whole Brain Radiation Brain Metastases From Solid Tumors NCT00879073 · started 2009 · scored riskier than 94% of active trials terminated
• Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma NCT00823797 · started 2008 · scored riskier than 69% of active trials completed
• An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. NCT01386580 · started 2011 · scored riskier than 83% of active trials completed
• Safety Evaluation of a Combination of Brain Radiation Therapy and Bevacizumab (Avastin®) for Treatment of Brain Metastasis NCT01332929 · started 2010 · scored riskier than 45% of active trials completed
• Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases NCT02595905 · started 2016 · scored riskier than 86% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.